Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
• AJICAP® Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody Drugs TOKYO, May 7th, 2025 – Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo) has been conducting joint research*…